Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

FORMA Therapeutics closes Series B financing to a total of $25.5 million

FORMA Therapeutics closes Series B financing to a total of $25.5 million

Despite reservations, smoking ban has not increased children's exposure to secondhand smoke

Despite reservations, smoking ban has not increased children's exposure to secondhand smoke

ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro

ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro

Xencor licenses its XmAb and Xtend technology platforms to Centocor Research & Development

Xencor licenses its XmAb and Xtend technology platforms to Centocor Research & Development

Micromet to present new results from its blinatumomab study at the ASH meeting

Micromet to present new results from its blinatumomab study at the ASH meeting

Minerva Biotechnologies grants Clarient exclusive commercializing rights to its MUC1 diagnostic test

Minerva Biotechnologies grants Clarient exclusive commercializing rights to its MUC1 diagnostic test

Researchers devise new tools for typing cells from children with acute lymphatic leukemia

Researchers devise new tools for typing cells from children with acute lymphatic leukemia

EMEA determines MAA for omacetaxine mepesuccinate for treatment of CML patients

EMEA determines MAA for omacetaxine mepesuccinate for treatment of CML patients

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

EMEA grants orphan drug status for LFB Biotechnologies' recombinant anti-CD20 monoclonal antibody

EMEA grants orphan drug status for LFB Biotechnologies' recombinant anti-CD20 monoclonal antibody

Bioniche Life Sciences announces the issuance of MCC patents in Japan

Bioniche Life Sciences announces the issuance of MCC patents in Japan

Faulty enzyme may contribute to malignant brain tumour formation

Faulty enzyme may contribute to malignant brain tumour formation

Medical care in Germany for children with cancer is very good: IQWiG report

Medical care in Germany for children with cancer is very good: IQWiG report

CytRx to initiate a multinational Phase 2 clinical trial of its doxorubicin prodrug

CytRx to initiate a multinational Phase 2 clinical trial of its doxorubicin prodrug

NCCN Guidelines adds ofatumumab and romidepsin as therapy options for CLL

NCCN Guidelines adds ofatumumab and romidepsin as therapy options for CLL

Mutated IDH1 gene linked to the progression of gliomas

Mutated IDH1 gene linked to the progression of gliomas

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at the ASH meeting

Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at the ASH meeting

Fred Hutchinson Cancer Research Center receives $10 million to advance biomedical research

Fred Hutchinson Cancer Research Center receives $10 million to advance biomedical research

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.